The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

資産クラス

Equity

運用会社

ALPS Funds

設定国

US

設定日

2014年12月30日

保有銘柄数

103

ISIN

US00162Q5936